


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented): An aqueous pharmaceutical composition comprising an oligopeptide of the formula I



in which

D and E each, independently of one another, denote Gly, Ala,  $\beta$ -Ala, Asn, Asp, Asp(OR), Arg, Cha, Cys, Gln, Glu, His, Ile, Leu, Lys, Lys(Ac), Lys(AcNH<sub>2</sub>), Lys(AcSH), Met, Nal, Nle, Orn, Phe, 4-Hal-Phe, homoPhe, Phg, Pro, Pya, Ser, Thr, Tia, Tic, Trp, Tyr or Val, where the said amino acid radicals may also be derivatised,

R denotes alkyl having 1-18 C atoms,

Hal denotes F, Cl, Br, I,

Ac denotes alkanoyl having 1-10 C atoms, aroyl having 7-11 carbon atoms or aralkanoyl having 8-12 C atoms,

n denotes a hydrogen atom or an alkyl radical R, benzyl or an aralkyl radical having 7-18 C atoms on the alpha-amino function of the corresponding amino acid radical,

with the proviso that at least one amino acid radical has a substituent n, where n denotes R,

and where, if they are radicals of optically active amino acids and amino acid derivatives, both the D and L forms are included,

and physiologically acceptable salts thereof,

and an etherified  $\beta$ -cyclodextrin having a water solubility of greater than 1.8 mg/ml of water.

2. (Previously Presented): An aqueous pharmaceutical composition according to Claim 1, wherein the etherified  $\beta$ -cyclodextrin present is a partially etherified  $\beta$ -cyclodextrin.
3. (Previously Presented): An aqueous pharmaceutical composition ~~preparation~~ according to Claim 1, wherein the ether substituents in the etherified  $\beta$ -cyclodextrin are hydroxymethyl, hydroxypropyl, or combinations thereof.
4. (Previously Presented): An aqueous pharmaceutical composition ~~preparation~~ according to Claim 1, wherein the etherified  $\beta$ -cyclodextrin has a molar degree of substitution of between 0.2 and 10.
5. (Previously Presented): An aqueous pharmaceutical composition according to Claim 4, wherein the partially etherified  $\beta$ -cyclodextrin has a molar degree of substitution of between 0.2 and 2, based on the ether substituents.
6. (Previously Presented): An aqueous pharmaceutical composition according to Claim 4, wherein the partially etherified  $\beta$ -cyclodextrin has a molar degree of substitution of between 0.5 and 0.8, based on the ether substituents.
7. (Previously Presented): An aqueous pharmaceutical composition according to Claim 1, wherein the oligopeptide is cilengitide.
8. (Previously Presented): An aqueous pharmaceutical composition according to Claim 1, further comprising an isotonicity agent in an amount necessary for establishing isotonicity.
9. (Previously Presented): An aqueous pharmaceutical composition according to Claim 1, wherein said composition has a pH of from 5 to 8.
10. (Previously Presented): An aqueous pharmaceutical composition according to Claim 9, wherein said composition has a pH of from 6 to 7.2.

11. (Previously Presented): An aqueous pharmaceutical composition according to Claim 1, wherein said oligopeptide is cilengitide and said etherified  $\beta$ -cyclodextrin is a hydroxypropyl- $\beta$ -cyclodextrin having a molar degree of substitution of from 0.5 to 0.8, and said composition contains from 20 to 120 mg/ml of cilengitide and from 15 to 25% by weight of said hydroxypropyl- $\beta$ -cyclodextrin.

12. (Previously Presented): An aqueous pharmaceutical composition according to Claim 11, wherein said composition contains about 80 mg/ml of cilengitide and about 20% by weight of hydroxypropyl- $\beta$ -cyclodextrin having a molar degree of substitution of about 0.58-0.73.

13. (Previously Presented): A process for the preparation of an aqueous pharmaceutical preparation according to Claim 1, said process comprising:

dissolving the  $\beta$ -cyclodextrin ether in water, and then subsequently adding the oligopeptide and any further adjuvants.

14. (Previously Presented): An aqueous pharmaceutical composition according to Claim 1, wherein said composition has a pH of from 5.6 to 7.4.

15. (Currently Amended): An aqueous pharmaceutical composition according to Claim 1, wherein said composition has a pH of from 6 to 7.2, and the osmolality is from 250 to 350 mOsmol/kg.

16. (Previously Presented): An aqueous pharmaceutical composition according to Claim 2, wherein the ether substituents in the etherified  $\beta$ -cyclodextrin are hydroxymethyl, hydroxypropyl, or combinations thereof.

17. (Previously Presented): An aqueous pharmaceutical composition according to Claim 4, wherein the partially etherified  $\beta$ -cyclodextrin has a molar degree of substitution of

0.58 - 0.73, based on the ether substituents.

18. (Currently Amended): An aqueous pharmaceutical composition according to Claim 1, wherein said oligopeptide is cyclo-(NMeArg-Gly-Asp-D-Phe-Val), cyclo-(Arg-Gly-Asp-DPhe-NMeVal), cyclo-(Arg-NMeGly-Asp-DPhe-Val), cyclo-(Arg-Gly-NMeAsp-DPhe-Val), or cyclo-(Arg-Gly-Asp-NMeDPhe-Val).

19. (Previously Presented): An aqueous pharmaceutical composition according to Claim 8, wherein said isotonicity agent is a physiologically tolerated salt, physiologically tolerated polyol, or a physiologically tolerated sugar.

20. (Previously Presented): An aqueous pharmaceutical composition according to Claim 19, wherein said isotonicity agent is sodium chloride, potassium chloride, glucose, glycerol or mannitol.

21. (Previously Presented): An aqueous pharmaceutical composition according to Claim 1, further comprising one or more physiologically tolerated adjuvants selected from antioxidants, preservatives, further stabilisers, structure formers and solubilizers.

22. (Previously Presented): An aqueous pharmaceutical composition according to Claim 1, further comprising one or more physiologically tolerated buffers, present in a concentration of from 5 mmol/l to 50 mmol/l.

23. (Previously Presented): An aqueous pharmaceutical composition according to Claim 1, wherein the osmolality is from 250 to 350 mOsmol/kg.